NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  
Step 1: Pre-submission of Application (Preparation)

Step 1: Pre-submission of Application (Preparation)

1

Apply QUEST 3+ Token

To conduct transactions for product registration, variation, licensing, renewal and other related transactions, you must register your membership and purchase your digital certificate in the form of USB token. Once you have obtained and installed your digital certificate, you will be able to conduct your transactions in QUEST 3+.

i.                     Apply Token HERE

ii.                   Read QUEST 3+ User Manual

2

Product classification

Before submission of application for a product registration, applicants may submit for product classification if unsure of the product category.

i.                     Download Product Classification Form

ii.                   Download Drug Regulation Guidance Document (DRGD)

iii.                 Download related Directive and Circular

3

Payment Mode

Three payment option available for applicants:

a.       Payment using company account (need to register company)

b.       Payment using personal credit card

c.       Cash Payment

4

Product Category: Generic (Scheduled Poison)

 

4.1

Patent and Data Exclusivity status

For the purpose of registration of generic products, Product Registration Holder shall provide patent declarations as below:

         i.            Product Registration Holder shall comply with all legal provisions in Malaysia;

       ii.            The government/ authority is not liable for any offence committed by the Product Registration Holder as a result of any breach of any law; and

     iii.            Product Registration Holder shall indemnify the government if any claim is made against the government as a result of any breach of any law by the applicant whether intentionally or otherwise.

Product Registration Holder shall conform to Patent Act 1983 (Act 291) and shall not market, sell, offer for sale, or store any registered product containing any patented active ingredient(s) of which the patent duration is yet to expire.

 

[Check Data Exclusivity List HERE]

 

4.2

Ensure availability of the following key documents.

This following list is not exhaustive, for details information, refer to checklist.

 

 

4.2.1

Registration dossiers in ICH CTD / ASEAN CTD format.

i.                     ICH CTD

ii.                   ASEAN CTD

Ø  Organization of the Dossier

Ø  Glossary used for the ACTD and ACTR

Ø  Part II: Quality

Ø  Part III: Nonclinical Document

Ø  Part IV: Clinical Document

Ø  ACTD Clinical Check List for Product Classification

Glossary:

ICH - The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use

CTD - Common Technical Document

 

 

4.2.2

GMP certificate status.

Local Manufacturer - Issued by National Pharmaceutical Regulatory Agency (NPRA) as stated in Drug Regulation Guidance Document (DRGD)

Note to follow for international manufacturer:

·                     PIC/S member countries (https://picscheme.org/en/members)

·                     Non-PIC/S member countries. GMP inspection by National Pharmaceutical Regulatory Agency (NPRA) GMP Inspectors is required.

Ø  Good Manufacturing Practice/Good Distribution Practice

Ø  Guidance Document Foreign GMP Inspection March 2018

Ø  Dokumen Panduan Keperluan Direktif Bilangan 2 Tahun 2014 dan Bilangan 2 Tahun 2015

 

 

4.2.3

CPP Certificate in WHO format (For imported product only).

A Certificate of Pharmaceutical Product which follows the format recommended by WHO shall be issued to locally manufactured products that are to be exported. For application of CPP, applicant shall fill in form BPFK 412.2: Permohonan Perakuan Keluaran Farmaseutikal.

Upon receipt of complete application, the certificate shall be issued within fifteen (15) working days.

 

 

4.2.4

Drug Master File or CEP Certificate including Annexes for the API.

NOTE: APPENDIX 6 OF DRGD (TO GET CONFIRMATION FROM API TEAM)

 

 

4.2.5

Zone IVB Stability data (according to ASEAN Stability Guidelines) – min. 12 months real time data (30oC C/75% RH) and 6 months accelerated conditions (40oC/75% RH)

 

 

4.2.6

Process Validation Report (according to ASEAN Guidelines).

 

 

4.2.7

Analytical Validation Report (according to ASEAN Guidelines) and Analytical procedure.

-          ASEAN Guidelines for Validation of Analytical Procedures

-          Guidance for protocol of Analysis

-          ICH website: Validation of analytical procedures texts and methodology Q2 (R1) [Download Q2(R1)]

-          API Administrative Procedure QUEST 3+

-          Template Letter for API Submission to PKK

-          ASEAN guidelines on Validation

-          NPRA website à Guideline Central à API à

 

(ICH reference is not listed in DRGD nor the NPRA website. Need to pull from ICH website)

 

 

4.2.8

Bioequivalence (BE) Study Report for Generic Products (according to ASEAN Guidelines).

-          Bioequivalence (BE)

-          Bioequivalence Study Reporting

 

 

4.2.9

Accreditation of Bioequivalence Center

1.       Page 202 & 203 of DRGD

2.       Relevant Directives under this link in NPRA website: Laman utama -> direktif -> lihat semua -> tab bioequivalence (BE)

http://npra.moh.gov.my/images/Circulars_Directive/Bioequivalence_BE/Direktif_Pusat_kajian_BE_1-1.pdf

http://npra.moh.gov.my/images/Circulars_Directive/Bioequivalence_BE/makluman-susulan-berkaitan-BE_120913-1.pdf

http://npra.moh.gov.my/images/Circulars_Directive/Bioequivalence_BE/img-602165902.pdf

http://npra.moh.gov.my/images/Circulars_Directive/Bioequivalence_BE/Direktif-Penguatkuasaan-BE_Effervescent-Dispersible-Etc-2.pdf

http://npra.moh.gov.my/images/Circulars_Directive/Bioequivalence_BE/160315_Kelulusan_Had_Maksimum_Yuran_Pemeriksaan_BE_dan_GLP.pdf

http://npra.moh.gov.my/images/Circulars_Directive/Bioequivalence_BE/160601_Lanjutan_Tarikh_Penguatkuasaan_untuk_Memenuhi_Keperluan_Kajian_Bioekuivalens_bagi_Produk_Generik.pdf

 

3.       NPRA website -> garis panduan-> tab clinical trial

http://npra.moh.gov.my/images/Guidelines_Central/Guidelines_on_Clinical_Trial/Malaysia%20Guideline%20for%20BE%20Inspection%20(5-9-14)%20-%20Final.pdf

 

4.       NPRA website -> industries -> regulatory information -> bioequivalence (BE) -> BE Studies Center

http://npra.moh.gov.my/index.php/regulatory-information/bioequivalence-be

 

5.       NPRA website -> industries -> application forms -> clinical trial forms

·         Borang PKPB/300/521

·         Borang PKPB/300/531   

·         Borang PKPB/300/551

·         Borang PKPB/300/552

 

 

 

 

 

Step 2: Submission
Step 3: Screening
Step 4: Evaluation of Application
Step 5: Regulatory Outcome
Step 6: Post-Registration Process

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Friday 01 November 2024, 09:13:24.

Search

Main Menu English